Shots:

• Merck KGaA to receive upfront- milestones- and royalties on net sales. Vertex to get exclusive license rights for Merck’s two DNA-dependent protein kinase (DNA-PK) inhibitors- M9831 (formerly known as VX-984) and a preclinical candidate for six genetic disease indications to fields of gene-editing
• Vertex will have an option to add indications to the above agreement and Merck will retain rights for its two DNA-PK candidates in all indication (EX- for Vertex) including oncology
• M9831 (formerly known as VX-984) is a DNA-PK inhibitor- evaluated in P-I for solid tumors. In 2017- Merck in-licensed Vertex’s four candidates including its VX-984 DNA-PK Inhibitors for DNA damage and repair

  Ref: Merck | Image: Merck KGaA